Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JOHN E POULOS

Allopathic & Osteopathic Physicians Internal Medicine Gastroenterology

NPI
1578596896
CMS profile
252436
Location
FAYETTEVILLE, NC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$85,974.32

105 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

By paying entity

PY2025 · entire year · sorted by reported total

Page 3 of 3; records 101–105 of 105 matching records. This page contains 5 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JOHN E POULOS

NPI 1578596896 · CMS profile ID 252436

Allopathic & Osteopathic Physicians / Internal Medicine / Gastroenterology

FAYETTEVILLE, NC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 3; records 101–105 of 105 matching records. This page contains 5 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1578596896?year=2025&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JOHN E POULOS, NPI 1578596896, CMS profile ID 252436. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–105 of 105 matching records. This page contains 5 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1578596896?year=2025&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). JOHN E POULOS, NPI 1578596896, CMS profile ID 252436. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–105 of 105 matching records. This page contains 5 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1578596896?year=2025&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
JOHN E POULOS, NPI 1578596896, CMS profile ID 252436, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–105 of 105 matching records. This page contains 5 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1578596896?year=2025&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

105 matching records · $85,974.32 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 105 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–105 of 105.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
PFIZER INC. $19.5101/14/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1231228374 CMS
ABBVIE INC. $4,025.0001/09/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1203668533 CMS
Lilly USA, LLC $23.9701/09/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1186726975 CMS
Ipsen Biopharmaceuticals, Inc $21.3401/08/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1208824865 CMS
ABBVIE INC. $116.5801/07/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1203668528 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $101,313.86 144
PY2020 $28,838.72 29
PY2021 $66,307.11 82
PY2022 $35,741.16 75
PY2023 $46,910.33 82
PY2024 $41,916.39 81
PY2025 $85,974.32 105

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $1,216.76 2
PY2025 Principal investigator $158,654.38 57
PY2024 Principal investigator $613,039.30 53
PY2023 Principal investigator $408,087.89 39
PY2022 Principal investigator $64,420.29 14
PY2021 Principal investigator $92,305.27 24
PY2020 Principal investigator $92,738.89 42
PY2019 Principal investigator $300,454.90 65

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

59 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Madrigal Pharmaceuticals $6,999.75 12/31/2025 Non-covered Recipient Entity
COASTAL RESEARCH INSTITUTE LLC
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248254895
Principal investigator 1 Madrigal Pharmaceuticals $22,632.75 12/22/2025 Non-covered Recipient Entity
COASTAL RESEARCH INSTITUTE LLC
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248254780
Principal investigator 1 Madrigal Pharmaceuticals $2,308.50 12/19/2025 Non-covered Recipient Entity
COASTAL RESEARCH INSTITUTE LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248254633
Principal investigator 1 Boehringer Ingelheim International GmbH $99.90 12/17/2025 Non-covered Recipient Entity
Coastal Research Institute
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220765442
Principal investigator 1 Boehringer Ingelheim International GmbH $109.50 12/17/2025 Non-covered Recipient Entity
Coastal Research Institute
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220765444
Principal investigator 1 Boehringer Ingelheim International GmbH $839.50 11/19/2025 Non-covered Recipient Entity
Coastal Research Institute
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220765438
Principal investigator 1 Boehringer Ingelheim International GmbH $10.00 11/19/2025 Non-covered Recipient Entity
Coastal Research Institute
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220765440
Principal investigator 1 Ipsen Bioscience Inc. $25.00 11/14/2025 Non-covered Recipient Entity
Coastal Research Institute, Llc
A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. (ELSPIRE) No dispute reported 06/30/2026 1176547279
Principal investigator 1 Ipsen Bioscience Inc. $206.00 11/14/2025 Non-covered Recipient Entity
Coastal Research Institute, Llc
A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. (ELSPIRE) No dispute reported 06/30/2026 1176547281
Principal investigator 1 Ipsen Bioscience Inc. $1,515.00 11/14/2025 Non-covered Recipient Entity
Coastal Research Institute, Llc
A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. (ELSPIRE) No dispute reported 06/30/2026 1176547283
Principal investigator 1 Ipsen Bioscience Inc. $7,500.00 11/14/2025 Non-covered Recipient Entity
Coastal Research Institute, Llc
A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. (ELSPIRE) No dispute reported 06/30/2026 1176547285
Principal investigator 1 Ipsen Bioscience Inc. $1,233.00 11/14/2025 Non-covered Recipient Entity
Coastal Research Institute, Llc
A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. (ELSPIRE) No dispute reported 06/30/2026 1176547287
Principal investigator 1 Ipsen Bioscience Inc. $3,000.00 11/14/2025 Non-covered Recipient Entity
Coastal Research Institute, Llc
A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. (ELSPIRE) No dispute reported 06/30/2026 1176547289
Principal investigator 1 Madrigal Pharmaceuticals $2,308.50 11/14/2025 Non-covered Recipient Entity
COASTAL RESEARCH INSTITUTE LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248252640
Principal investigator 1 Madrigal Pharmaceuticals $2,308.50 10/29/2025 Non-covered Recipient Entity
COASTAL RESEARCH INSTITUTE LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248252214
Principal investigator 1 Madrigal Pharmaceuticals $2,308.50 10/16/2025 Non-covered Recipient Entity
COASTAL RESEARCH INSTITUTE LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248251598
Principal investigator 1 Madrigal Pharmaceuticals $1,987.88 09/23/2025 Non-covered Recipient Entity
COASTAL RESEARCH INSTITUTE LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248250684
Principal investigator 1 Madrigal Pharmaceuticals $2,496.82 09/05/2025 Non-covered Recipient Entity
COASTAL RESEARCH INSTITUTE LLC
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248249799
Principal investigator 1 Boehringer Ingelheim International GmbH $12.24 08/26/2025 Non-covered Recipient Entity
Coastal Research Institute
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220765426
Principal investigator 1 Boehringer Ingelheim International GmbH $151.58 08/26/2025 Non-covered Recipient Entity
Coastal Research Institute
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220765428
Principal investigator 1 Boehringer Ingelheim International GmbH $139.86 08/26/2025 Non-covered Recipient Entity
Coastal Research Institute
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220765430
Principal investigator 1 Boehringer Ingelheim International GmbH $620.50 08/26/2025 Non-covered Recipient Entity
Coastal Research Institute
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220765432
Principal investigator 1 Boehringer Ingelheim International GmbH $39.08 08/26/2025 Non-covered Recipient Entity
Coastal Research Institute
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220765434
Principal investigator 1 Boehringer Ingelheim International GmbH $5.00 08/26/2025 Non-covered Recipient Entity
Coastal Research Institute
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220765436
Principal investigator 1 Boehringer Ingelheim International GmbH $151.58 08/26/2025 Non-covered Recipient Entity
Coastal Research Institute
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220765446
Principal investigator 1 Boehringer Ingelheim International GmbH $139.86 08/26/2025 Non-covered Recipient Entity
Coastal Research Institute
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220765448
Principal investigator 1 Boehringer Ingelheim International GmbH $620.50 08/26/2025 Non-covered Recipient Entity
Coastal Research Institute
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220765450
Principal investigator 1 Boehringer Ingelheim International GmbH $39.08 08/26/2025 Non-covered Recipient Entity
Coastal Research Institute
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220765452
Principal investigator 1 Boehringer Ingelheim International GmbH $5.00 08/26/2025 Non-covered Recipient Entity
Coastal Research Institute
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220765454
Principal investigator 1 Boehringer Ingelheim International GmbH $2.14 08/11/2025 Non-covered Recipient Entity
Coastal Research Institute
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220765408
Principal investigator 1 Boehringer Ingelheim International GmbH $12.86 08/11/2025 Non-covered Recipient Entity
Coastal Research Institute
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220765410
Principal investigator 1 Boehringer Ingelheim International GmbH $328.00 08/11/2025 Non-covered Recipient Entity
Coastal Research Institute
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220765412
Principal investigator 1 Boehringer Ingelheim International GmbH $5.52 08/11/2025 Non-covered Recipient Entity
Coastal Research Institute
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220765414
Principal investigator 1 Boehringer Ingelheim International GmbH $15.00 08/11/2025 Non-covered Recipient Entity
Coastal Research Institute
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220765416
Principal investigator 1 Boehringer Ingelheim International GmbH $14.90 08/11/2025 Non-covered Recipient Entity
Coastal Research Institute
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220765418
Principal investigator 1 Boehringer Ingelheim International GmbH $40.00 08/11/2025 Non-covered Recipient Entity
Coastal Research Institute
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220765420
Principal investigator 1 Boehringer Ingelheim International GmbH $190.50 08/11/2025 Non-covered Recipient Entity
Coastal Research Institute
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220765422
Principal investigator 1 Boehringer Ingelheim International GmbH $33.71 08/11/2025 Non-covered Recipient Entity
Coastal Research Institute
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220765424
Principal investigator 1 Madrigal Pharmaceuticals $1,987.88 08/07/2025 Non-covered Recipient Entity
COASTAL RESEARCH INSTITUTE LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248248239
Principal investigator 1 Madrigal Pharmaceuticals $2,284.20 07/31/2025 Non-covered Recipient Entity
COASTAL RESEARCH INSTITUTE LLC
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248247962
Principal investigator 1 Madrigal Pharmaceuticals $1,987.88 07/31/2025 Non-covered Recipient Entity
COASTAL RESEARCH INSTITUTE LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248247966
Recipient Eli Lilly and Company $273.88 07/16/2025 Covered Recipient Physician A PHASE 3B, RANDOMIZED, MULTICENTER, CONTROLLED STUDY OF MIRIKIZUMAB AND PLACEBO OR MIRIKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS AND OBESITY OR OVERWEIGHT No dispute reported 06/30/2026 1187872441
Recipient Eli Lilly and Company $942.88 07/16/2025 Covered Recipient Physician A PHASE 3B, RANDOMIZED, MULTICENTER, CONTROLLED STUDY OF MIRIKIZUMAB AND PLACEBO OR MIRIKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE AND OBESITY OR OVERWEIGHT No dispute reported 06/30/2026 1187876349
Principal investigator 1 Madrigal Pharmaceuticals $6,573.15 07/10/2025 Non-covered Recipient Entity
COASTAL RESEARCH INSTITUTE LLC
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248247009
Principal investigator 1 Madrigal Pharmaceuticals $1,987.88 07/10/2025 Non-covered Recipient Entity
COASTAL RESEARCH INSTITUTE LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248247013
Principal investigator 1 Madrigal Pharmaceuticals $1,987.88 06/19/2025 Non-covered Recipient Entity
COASTAL RESEARCH INSTITUTE LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248245884
Principal investigator 1 Madrigal Pharmaceuticals $2,488.05 06/12/2025 Non-covered Recipient Entity
COASTAL RESEARCH INSTITUTE LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248245497
Principal investigator 1 Madrigal Pharmaceuticals $1,354.72 05/23/2025 Non-covered Recipient Entity
COASTAL RESEARCH INSTITUTE LLC
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248244437
Principal investigator 1 Madrigal Pharmaceuticals $2,488.05 05/22/2025 Non-covered Recipient Entity
COASTAL RESEARCH INSTITUTE LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248244304
Principal investigator 1 Genentech, Inc. $30,492.00 05/16/2025 Non-covered Recipient Entity
COASTAL RESEARCH INSTITUTE LLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211588665
Principal investigator 1 Madrigal Pharmaceuticals $7,105.05 05/15/2025 Non-covered Recipient Entity
COASTAL RESEARCH INSTITUTE LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248243869
Principal investigator 1 Ipsen Bioscience Inc. $1,952.00 04/23/2025 Non-covered Recipient Entity
Coastal Research Institute, Llc
A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. (ELSPIRE) No dispute reported 06/30/2026 1176547277
Principal investigator 1 Madrigal Pharmaceuticals $4,719.60 04/08/2025 Non-covered Recipient Entity
COASTAL RESEARCH INSTITUTE LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248241868
Principal investigator 1 Ipsen Bioscience Inc. $2,767.00 03/25/2025 Non-covered Recipient Entity
Coastal Research Institute, Llc
A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. (ELSPIRE) No dispute reported 06/30/2026 1176547275
Principal investigator 1 Genentech, Inc. $1,386.00 03/07/2025 Non-covered Recipient Entity
COASTAL RESEARCH INSTITUTE LLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211588656
Principal investigator 1 Madrigal Pharmaceuticals $9,171.17 03/06/2025 Non-covered Recipient Entity
COASTAL RESEARCH INSTITUTE LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248240282
Principal investigator 1 Madrigal Pharmaceuticals $10,926.91 02/06/2025 Non-covered Recipient Entity
COASTAL RESEARCH INSTITUTE LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248239112
Principal investigator 1 Genentech, Inc. $3,465.00 01/14/2025 Non-covered Recipient Entity
COASTAL RESEARCH INSTITUTE LLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211588662
Principal investigator 1 Madrigal Pharmaceuticals $3,073.95 01/03/2025 Non-covered Recipient Entity
COASTAL RESEARCH INSTITUTE LLC
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248237878